NYSE American - Nasdaq Real Time Price USD

VolitionRx Limited (VNRX)

0.5059

+0.0429

+(9.27%)

At close: April 29 at 4:00:00 PM EDT

0.4829

-0.02

(-4.55%)

After hours: April 29 at 6:54:40 PM EDT

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that President and Group Chief Executive Officer, Cameron Reynolds, has issued a Shareholder Letter providing a business update.

PR Newswire 14 hours ago

VNRX
+9.27%
VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances

VolitionRX Ltd (VNRX) reports a 59% revenue increase, driven by the Nu.Q Vet Cancer Test, while reducing operating expenses and advancing key studies and licensing deals.

GuruFocus.com 28 days ago

VNRX
+9.27%
VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces financial results and a business update for the fourth quarter and full fiscal year ended December 31, 2024. Volition management will host a conference call today, March 31 at 4:30 p.m. U.S. Eastern Time to discuss these results. Conference call details can be found below.

PR Newswire 29 days ago

VNRX
+9.27%
Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces two poster presentations at the European Society for Medical Oncology (ESMO)'s European Lung Cancer Congress 2025 (ELCC 2025). The studies demonstrate how Volition's Nu.Q® H3K27Me3 biomarker, when combined with circulating tumor DNA, may improve the prognostic value for overall survival and could help inform treatment decisions in Non Small Cell Lung Cancer (NSCLC); and how Volition's Nu.

PR Newswire last month

VNRX
+9.27%
Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces it will host a virtual investor event on Wednesday, April 9, 2025, at 10:00 AM ET, featuring Volition's Gael Forterre, Chief Commercial Officer, Dr. Andrew Retter, Chief Medical Officer and Dr. Jake Micallef, Chief Scientific Officer. To register, click here.

PR Newswire last month

VNRX
+9.27%
VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announces today that it has entered into definitive agreements for the purchase and sale of (i) 2,363,636 shares of its common stock to certain directors, executive officers, and certain existing stockholders of the Company (collectively, the "Insiders") at an offering price of $0.55 per share, and (ii) 1,739,087 shares of its common stock, together with common stock purchase warrants to

PR Newswire last month

VNRX
+9.27%
VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition") today announces that it will host a conference call on Monday, March 31 at 4.30 p.m. U.S. Eastern Time to discuss its financial and operating results for the fourth quarter and full fiscal year 2024, in addition to providing a business update. Details of this event can be found below.

PR Newswire last month

VNRX
+9.27%
Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

VolitionRx Limited (NYSE AMERICAN: VNRX) ('Volition'), a multi-national epigenetics company, today announces the results of a study which shows that an automated Nu.Q® Cancer immunoassay test in development detected a range of 21 different cancers. This could potentially be used as a standalone pan-cancer test or, given its low false positive rate among healthy people, be licensed out for use in conjunction with other liquid biopsy technologies to improve accuracy.

PR Newswire last month

VNRX
+9.27%
Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces the release of Volition's new lung cancer primer, "Lung Cancer: Hope of a Brighter Tomorrow." The report introduces Volition's Nu.Q® Cancer assays2 in development to revolutionize the early detection and monitoring of lung cancer via easy to administer and low-cost assays which will utilize only a small amount of blood.

PR Newswire last month

VNRX
+9.27%
Volition Proudly Sponsors the 44th ISICEM Congress

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announced its participation at the 44th Annual ISICEM ("International Symposium on Intensive Care & Emergency Medicine") Congress in Brussels Belgium being held from March 18-21. As a silver sponsor, Volition will support multiple presentations highlighting the Company's Nu.Q® H3.1 epigenetic screening technology in intensive care and emergency medicine settings.

PR Newswire last month

VNRX
+9.27%
Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer Test supply agreement (the "Agreement") with Fujifilm Vet Systems Co. Ltd ("Fujifilm Vet Systems") in Japan, to include Volition's chemiluminescent immunoassay (ChLIA) version of the Test via the Immunodiagnostic Systems (IDS) i10® automated analyzer platform, for a new five year initial term. Previously, the Agreement enabled Fujifilm Vet Systems to

PR Newswire last month

VNRX
+9.27%
Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, announces first patient enrollment in a clinical study evaluating the company's proprietary Nu.Q® Cancer technology for distinguishing between malignant and benign pulmonary nodules in patients undergoing low-dose computed tomography (LDCT) screening for lung cancer. The study, in collaboration with National Taiwan University Hospital, is entitled "Epigenetic Nucleosomes in Plasma for Pulmonary Nodule Di

PR Newswire last month

VNRX
+9.27%
VNRX: Additional clinical papers & company webinars provide insights to Volition’s progress. Nu.Q Discover biomarkers selected for clinical trial. Management continues to focus on signing licensing deals for Capture-PCR & Nu.Q NETs

By Steven Ralston, CFA NYSE:VNRX READ THE FULL VNRX RESEARCH REPORT RECENT EVENTS Nu.Q Discover to be Utilized in a Human Clinical Study On March 4, 2025, VolitionRx (NYSE:VNRX) made a significant milestone announcement that, for the first time, Nu.Q Discover biomarkers will be utilized in a human clinical study . An unnamed leading pharmaceutical company will be using two Nu.Q Discover

Zacks Small Cap Research last month

VNRX
+9.27%
Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announces that it has signed an agreement with a leading pharmaceutical company to utilize Volition's Nu.Q® Discover biomarkers in a longitudinal Phase 1/2b study. The Nu.Q® Discover program provides drug developers and scientists with a range of state-of-the-art assays for rapid epigenetic profiling in disease model development, preclinical testing, and clinical studies from discovery to market re

PR Newswire last month

VNRX
+9.27%
Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, Volition is pleased to announce our participation in the 97th Annual Western Veterinary Conference (WVC), one of the largest and longest-running veterinary conferences in the United States, attracting approximately 20,000 veterinary professionals. The conference will take place from March 2-5, 2025, in Las Vegas, NV.

PR Newswire last month

VNRX
+9.27%
Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

VolitionRx Limited (NYSE AMERICAN: VNRX) Volition a multi-national epigenetics company, announces its first commercial sale of Volition's High Throughput Synthetic Sepsis method that measures Neutrophil Extracellular Traps "NETs" activation and inhibition in whole blood in real time, helping companies develop new therapeutics to combat sepsis and other NETs-related disease.

PR Newswire 2 months ago

VNRX
+9.27%
Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it will host a virtual investor event on Friday, February 14, 2025 at 8:00 AM ET, featuring Volition company management Dr. Andrew Retter, Chief Medical Officer and Gael Forterre, Chief Commercial Officer. To register, click here.

PR Newswire 2 months ago

VNRX
+9.27%
Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced the results of a large-scale study which shows that its Nu.Q®NETs H3.1 biomarker is an independent predictor of 28-day mortality and need for renal replacement therapy (RRT) in sepsis and septic shock patients.

PR Newswire 2 months ago

VNRX
+9.27%
Volition Issues Business Review 2024

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, has issued a Business Review of 2024, outlining its key highlights from the past year.

PR Newswire 3 months ago

VNRX
+9.27%
VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition" or the "Company"), a multi-national epigenetics company, announced that it has retained LifeSci Advisors, LLC ("LSA") a premiere life sciences corporate and financial communications agency, to provide investor relations advisory services.

PR Newswire 4 months ago

VNRX
+9.27%

Performance Overview

Return	VNRX	S&P 500 (^GSPC)
YTD	-15.68%	-5.45%
1-Year	-41.17%	+8.69%
3-Year	-81.87%	+34.58%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

VolitionRx Limited (VNRX)

VolitionRX Limited: Revolutionizing the diagnosis and monitoring of life-altering diseases for both humans and animals in multi-billion dollar markets

VolitionRX Ltd (VNRX) Q4 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advances

VolitionRx Limited Announces Full Fiscal Year 2024 Financial Results and Business Update

Volition Announces Two Poster Presentations at ESMO's European Lung Cancer Congress 2025

Volition to Host Virtual Investor Event on Nu.Q® Cancer, "A Look to the Future of Cancer Diagnostics", on April 9, 2025

VolitionRx Announces Pricing of up to $2.3 Million Registered Direct Offering

VolitionRx Limited Schedules Full Fiscal Year 2024 Earnings Conference Call and Business Update

Volition's Nu.Q® Cancer Diagnostics Test Aims To Disrupt the Multi-Billion Dollar Liquid Biopsy Industry

Volition Introduces Nu.Q® Cancer Blood Test in New Industry Primer for Lung Cancer

Volition Proudly Sponsors the 44th ISICEM Congress

Volition Signs first ever Nu.Q® Vet Cancer Test Automation Agreement with Fujifilm Vet Systems

Volition Announces First Patient Enrolled in NTU Hospital's Prospective Validation Study of Nu.Q® Lung Cancer Test

VNRX: Additional clinical papers & company webinars provide insights to Volition’s progress. Nu.Q Discover biomarkers selected for clinical trial. Management continues to focus on signing licensing deals for Capture-PCR & Nu.Q NETs

Volition's Nu.Q® Discover Biomarkers to be utilized in Human Clinical Study Sponsored by Leading Pharmaceutical Company for the First Time

Volition Showcases Nu.Q® Vet Cancer Test at the 97th WVC Annual Conference

Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis

Volition to Host Virtual Investor Event on Nu.Q® NETs, "Casting a New Light on Sepsis Management", on February 14, 2025

Large clinical study establishes Nu.Q® NETs H3.1 as an independent predictor of 28-day mortality in sepsis

Volition Issues Business Review 2024

VolitionRx Appoints LifeSci Advisors as Investor Relations Consultants

Performance Overview